Medicenna to Present at Upcoming November 2018 Scientific Conferences

TORONTO and HOUSTON, Nov. 7, 2018 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, will be presenting an update on previously announced data from the Company's MDNA109 and MDNA55 programs at the following conferences:

33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) held from November 7 to 11, 2018


Preclinical characterization of IL-2 Superkines engineered with biased CD8+
T cell stimulating properties


Poster #:




Friday, November 9th 2018 from 12:45 pm to 6:30 pm EST



Hall E, Walter E. Washington Convention Center in Washington, D.C. 


23rd Annual Meeting of the Society of Neuro-Oncology (SNO) held from November 15 to 18, 2018


Dr. Achal Singh Achrol, MD; Director of the Neurosurgery Clinical Trials 
Program and Chief of the Glioma Surgery Program at the John Wayne Cancer Institute and Pacific Neuroscience Institute



Intratumoral Delivery of MDNA55, an Interleukin­4 Receptor Targeted Immunotherapy, by MRI-Guided Convective Delivery for the Treatment of Recurrent Glioblastoma


Poster #: 




Friday, November 16, 2018 from 7:30pm to 9:30pm CST



Marriott Hotel, New Orleans, 555 Canal Street, New Orleans, Louisiana 


About Medicenna
Medicenna is a clinical stage immunotherapy company focused on oncology and the development and commercialization of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines™ and first in class Empowered Cytokines™ (ECs) for the treatment of a broad range of cancers.  Medicenna's wholly owned subsidiary, Houston-based Medicenna BioPharma, is specifically targeting the Interleukin-4 Receptor (IL4R), which is over-expressed by at least 20 different types of cancer affecting more than one million new cancer patients every year. Supported by a significant non-dilutive grant from CPRIT (Cancer Prevention and Research Institute of Texas), Medicenna's lead IL4-EC, MDNA55 is enrolling patients in a Phase 2b clinical trial for recurrent glioblastoma (rGBM), the most common and uniformly fatal form of brain cancer, at top-ranked brain cancer centres in the US. MDNA55 has completed three clinical trials in 72 patients, including 66 adults with rGBM, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA respectively. For more information, please visit

Cision View original content:

SOURCE Medicenna Therapeutics Corp.

Company Codes: OTC-QX:MDNAF, Toronto:MDNA  

Back to news